Last reviewed · How we verify
Modified Bolus 5-FU/LV with Irinotecan
Modified Bolus 5-FU/LV with Irinotecan is a Chemotherapy combination regimen Small molecule drug developed by Pfizer. It is currently in Phase 3 development for Metastatic colorectal cancer, Advanced gastric cancer.
This combination regimen inhibits DNA synthesis through fluorouracil and topoisomerase I inhibition via irinotecan, with leucovorin enhancing fluorouracil efficacy.
This combination regimen inhibits DNA synthesis through fluorouracil and topoisomerase I inhibition via irinotecan, with leucovorin enhancing fluorouracil efficacy. Used for Metastatic colorectal cancer, Advanced gastric cancer.
At a glance
| Generic name | Modified Bolus 5-FU/LV with Irinotecan |
|---|---|
| Sponsor | Pfizer |
| Drug class | Chemotherapy combination regimen |
| Target | Thymidylate synthase (5-FU), Topoisomerase I (irinotecan) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
5-Fluorouracil (5-FU) is a thymidylate synthase inhibitor that disrupts DNA synthesis and repair. Irinotecan is a topoisomerase I inhibitor that prevents DNA unwinding and causes double-strand breaks during replication. Leucovorin (folinic acid) potentiates 5-FU by stabilizing its binding to thymidylate synthase, enhancing cytotoxic effects. This triplet combination targets cancer cells through complementary mechanisms of action.
Approved indications
- Metastatic colorectal cancer
- Advanced gastric cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea/vomiting
- Anemia
- Mucositis
- Fatigue
- Thrombocytopenia
Key clinical trials
- Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer (PHASE2)
- Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells (PHASE3)
- Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Modified Bolus 5-FU/LV with Irinotecan CI brief — competitive landscape report
- Modified Bolus 5-FU/LV with Irinotecan updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Modified Bolus 5-FU/LV with Irinotecan
What is Modified Bolus 5-FU/LV with Irinotecan?
How does Modified Bolus 5-FU/LV with Irinotecan work?
What is Modified Bolus 5-FU/LV with Irinotecan used for?
Who makes Modified Bolus 5-FU/LV with Irinotecan?
What drug class is Modified Bolus 5-FU/LV with Irinotecan in?
What development phase is Modified Bolus 5-FU/LV with Irinotecan in?
What are the side effects of Modified Bolus 5-FU/LV with Irinotecan?
What does Modified Bolus 5-FU/LV with Irinotecan target?
Related
- Drug class: All Chemotherapy combination regimen drugs
- Target: All drugs targeting Thymidylate synthase (5-FU), Topoisomerase I (irinotecan)
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic colorectal cancer
- Indication: Drugs for Advanced gastric cancer
- Compare: Modified Bolus 5-FU/LV with Irinotecan vs similar drugs
- Pricing: Modified Bolus 5-FU/LV with Irinotecan cost, discount & access